Abstract
Aim: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world. Patients & methods: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics. Results: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes. Conclusion: In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.
| Language | English |
|---|---|
| Pages | 33-44 |
| Number of pages | 12 |
| Journal | Future Oncology |
| Volume | 15 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1 2019 |
Fingerprint
Keywords
- database
- eribulin mesylate
- metastatic breast cancer
- real-world
- safety
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Eribulin in the treatment of advanced breast cancer : Real-world scenario from 39 Italian centers - ESEMPiO study. / Barni, Sandro; Livraghi, Luca; Morritti, Maria; Vici, Patrizia; Michelotti, Andrea; Cinieri, Saverio; Fontanella, Caterina; Porcu, Luca; Del Mastro, Lucia; Puglisi, Fabio.
In: Future Oncology, Vol. 15, No. 1, 01.01.2019, p. 33-44.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Eribulin in the treatment of advanced breast cancer
T2 - Future Oncology
AU - Barni, Sandro
AU - Livraghi, Luca
AU - Morritti, Maria
AU - Vici, Patrizia
AU - Michelotti, Andrea
AU - Cinieri, Saverio
AU - Fontanella, Caterina
AU - Porcu, Luca
AU - Del Mastro, Lucia
AU - Puglisi, Fabio
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Aim: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world. Patients & methods: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics. Results: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes. Conclusion: In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.
AB - Aim: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world. Patients & methods: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics. Results: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes. Conclusion: In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.
KW - database
KW - eribulin mesylate
KW - metastatic breast cancer
KW - real-world
KW - safety
UR - http://www.scopus.com/inward/record.url?scp=85058484815&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058484815&partnerID=8YFLogxK
U2 - 10.2217/fon-2018-0324
DO - 10.2217/fon-2018-0324
M3 - Article
VL - 15
SP - 33
EP - 44
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 1
ER -